Marchex Inc (MCHX)
NASDAQCommunication ServicesAdvertising AgenciesSnapshot 2026-09-04
$1.74-1.14%
Close 2026-09-04 · 1-day change
NASDAQCommunication ServicesAdvertising AgenciesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Marchex aims to improve profit margins to 10% or more. It plans sequential revenue growth in 2026. The recent acquisition of Archenia should enhance earnings. The stock has gained nearly 15% in the last month.
Marchex is still loss-making and has missed recent earnings. Revenue declined from $11.65M in 2025-Q2 to $10.62M in 2026-Q1. The company faces volatile management and sector headwinds. Debt from recent equity sales adds risk.
The market has no clear consensus revenue or EPS growth priced in. Analyst estimates show a small EPS of $0.05 for 2026 and revenue near $44.9M. Our view is cautious given the company’s losses and mixed execution.
Breaks if: Adjusted EBITDA margin falls below 5% in FY26
Marchex aims to achieve Adjusted EBITDA margins of 10% or more by combining revenue growth with lower operating expenses.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is a turnaround story, as MCHX is currently loss-making and has volatile management. The thesis is in a watch state, indicating that the company is under scrutiny for its ability to improve fundamentals.
The market seems to have priced in elevated risks due to recent earnings misses and a weak financial backdrop. Expectations may be low, especially given the company's performance compared to industry peers.
Management is focused on achieving adjusted EBITDA margins of 10% or more and sequential revenue growth. However, recent results have been mixed, with a decline in revenue but some improvement following the acquisition of Archenia.
The future of MCHX depends on its ability to meet guidance and improve financial metrics. Additionally, the performance of sector bellwethers like OMC, TTD, and MGNI will be crucial in determining if MCHX can benefit from sector momentum or face headwinds.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The completion of the Archenia acquisition supports integration capabilities and revenue growth. There are no new threats impacting the thesis at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Acquisition not closed by end of 2026-Q3
Breaks if: Any quarter in 2026 shows revenue decline from prior quarter
Achieve sequential quarterly revenue growth throughout 2026, targeting approximately 10% run rate growth from 2025 year-end levels.
Stated as a priority in 3 of last 3 quarters. Revenue declined from $11.7 million in 2025-Q2 to $11.0 million in 2026-Q2, but pro forma combined revenue including Archenia rose to $15.5 million in 2026-Q2 with guidance for further sequential growth to $16.0-$16.5 million in 2026-Q3. The trajectory shows mixed delivery with recent improvement post-acquisition.
“Pro forma combined revenue was $15.5 million for Q2 2026, with guidance for $16.0 - $16.5 million in Q3 2026.”
“Marchex currently anticipates sequential quarterly revenue increases during 2026 and revenue growth on a run rate basis in the 10% range from 2025 year-end levels.”
“Revenue was $11.7 million in Q2 2025 and $11.0 million in Q2 2026, with pro forma combined revenue increasing to $15.5 million in Q2 2026.”
In the next 1 to 3 years, MCHX's performance will largely depend on management execution and sector dynamics. Not investment advice.